- Home
- SURG vs IMMX Comparison
SURG vs IMMX Comparison
Compare SURG & IMMX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SURG
- IMMX
- Stock Information
- Founded
- SURG 2006
- IMMX 2014
- Country
- SURG United States
- IMMX United States
- Employees
- SURG N/A
- IMMX N/A
- Industry
- SURG Advertising
- IMMX Medicinal Chemicals and Botanical Products
- Sector
- SURG Consumer Discretionary
- IMMX Health Care
- Exchange
- SURG Nasdaq
- IMMX Nasdaq
- Market Cap
- SURG 64.1M
- IMMX 61.1M
- IPO Year
- SURG N/A
- IMMX 2021
- Fundamental
- Price
- SURG $2.94
- IMMX $2.71
- Analyst Decision
- SURG Strong Buy
- IMMX Strong Buy
- Analyst Count
- SURG 1
- IMMX 1
- Target Price
- SURG $9.00
- IMMX $7.00
- AVG Volume (30 Days)
- SURG 68.8K
- IMMX 204.0K
- Earning Date
- SURG 08-12-2025
- IMMX 08-11-2025
- Dividend Yield
- SURG N/A
- IMMX N/A
- EPS Growth
- SURG N/A
- IMMX N/A
- EPS
- SURG N/A
- IMMX N/A
- Revenue
- SURG $40,029,467.00
- IMMX N/A
- Revenue This Year
- SURG $57.76
- IMMX N/A
- Revenue Next Year
- SURG $112.61
- IMMX N/A
- P/E Ratio
- SURG N/A
- IMMX N/A
- Revenue Growth
- SURG N/A
- IMMX N/A
- 52 Week Low
- SURG $1.05
- IMMX $1.26
- 52 Week High
- SURG $3.47
- IMMX $3.20
- Technical
- Relative Strength Index (RSI)
- SURG 46.76
- IMMX 53.07
- Support Level
- SURG $2.86
- IMMX $2.74
- Resistance Level
- SURG $3.13
- IMMX $3.20
- Average True Range (ATR)
- SURG 0.15
- IMMX 0.21
- MACD
- SURG -0.02
- IMMX -0.01
- Stochastic Oscillator
- SURG 13.56
- IMMX 23.44
About SURG SurgePays Inc.
Surgepays Inc is a fintech company focused on the underbanked community. It provides services to financial technology, telecommunications, and digital media companies. Its operating segment includes Mobile Virtual Network Operators that provide mobile broadband (internet connectivity), voice and SMS text messaging to both subsidized and direct retail prepaid customers through SurgePhone Wireless, LLC and Torch Wireless, LLC; Comprehensive Platform Services provide financial technology and a wireless top-up platform to independently owned convenience stores throughout the country; and Others. It generates the majority of its revenue from the Mobile Virtual Network Operators segment.
About IMMX Immix Biopharma Inc.
Immix Biopharma Inc is engaged in the discovery and development of novel cell therapies for hematologic malignancies (blood cancers) and other indications. It is a clinical-stage biopharmaceutical company developing a novel class of Tissue-Specific Therapeutics TM in oncology and inflammation. Its TME Normalization Technology allows drug candidates to circulate in the bloodstream, exit through tumor blood vessels and simultaneously attack all components of the TME. Its product candidates include CAR-T NXC-201 for autoimmune diseases, and IMX-110 for treatment of soft tissue sarcoma.